|Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA||Exec. Chairman||80k||N/A||1952|
|Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA||CEO & Exec. Director||1.41M||N/A||1966|
|Mr. Johnny Cheng C.A., BEc, CA||CFO & Exec. Director||788.96k||N/A||1967|
|Dr. Wei-Guo Su B.Sc., Ph.D.||Chief Scientific Officer, Exec. VP & Exec. Director||1.21M||N/A||1957|
|Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, MA, EdM, Solicito||Company Sec. & Non-Exec. Director||70k||N/A||1952|
|Mr. Mark Lee||Sr. VP of Corp. Fin. & Devel.||N/A||N/A||1977|
|Mr. Charles Nixon||Group Gen. Counsel||N/A||N/A||N/A|
|Mr. Andrew Shih||Sr. VP of HR - Organization & Leadership Devel.||N/A||N/A||N/A|
|Dr. May Wang||Sr. VP of Bus. Devel. & Strategic Alliances||N/A||N/A||1963|
|Mr. Hong Chen||Chief Commercial Officer - China, GM - Hutchison Sinopharm & GM - Hutchison Healthcare||N/A||N/A||1970|
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Hutchison China MediTech Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.